卡巴拉汀

酒石酸卡巴拉汀是一种乙酰胆碱酯酶抑制剂，用于治疗中、轻度老年痴呆症（即阿尔茨海默氏症：AD），目前已在瑞士上市，市场前景看好。

Rivastigmine , a sort of acetylcholinesterase inhibitor , is used in the symptomatic treatment of mild to moderate Alzheimer 's Disease ( AD ) . Now it has been launched in Switzerland , and the market prospect is very good .

方法：实验于2004-11在暨南大学附属第一医院进行，应用Meta分析方法对5项研究卡巴拉汀治疗AD的自身前后对照实验进行再分析，评价其综合的显著性差异和效应大小。

METHODS : The experiment was finished in the First Affiliated Hospital of Jinan University in November 2004.Five self - controlled trials of rivastigmine in the treatment of AD were analyzed with Meta - analysis , and synthetically significant difference and effect size were evaluated .

结论卡巴拉汀和多奈哌齐可显著改善AD患者的认知功能、痴呆程度和日常生活能力，疗效相当，较为安全，耐受性好。

ConclusionRivastigmine and donepezil both similarly improve cognition , dementia degree and daily living ability in AD patients with generally good toleration and safety .

脑卒中VD组服用胆碱酯酶抑制剂重酒石酸卡巴拉汀，半年后复查头颅MRI、磁共振波谱分析（MRS）及认知功能。

The patients with VD were prescribed rivastigmine hydrogen tartrate (" Exelon ", Norvatis ), and given MRS assessment half a year later .

卡巴拉汀治疗血管性痴呆的开放性多中心随机对照研究

Clinical efficacy and safety of rivastigmine in treatment of vascular dementia : a multi-center , open-label , randomized , controlled trial

卡巴拉汀治疗阿尔茨海默病患者的临床研究

The treatment by using rivastigmine for patients with Alzheimer disease : results of a multicenter , randomized , open-labeled , controlled clinical trial

采用O/W、W1/O/W2乳化溶剂挥发法和喷雾干燥法制备的卡巴拉汀微球24小时内释放量相对较高。

Microspheres manufactured by O / W , W1 / O / W2 emulsification-solvent evaporation method and spray drying showed relative high release rate of rivastigmine in the period of preliminary 24 hours .